EUCTR2005-000428-18-GB进行中（未招募）1 期
A mulit-center, randomized, double-blind, placebo-controlled, four-arm parallel group trial to investigate the efficacy and safety of three different transdermal doses of rotigotine in subjects with idiopathic restless legs syndrome
Schwarz Biosciences GmbH0 个研究点目标入组 450 人开始时间: 2005年4月18日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 450
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •1. Subject is informed and given ample time and opportunity to think about her/his
- •participation and has given her/his written informed consent.
- •2. Subject understands the investigational nature of the trial and is willing and able
- •to comply with the trial requirements. Subject is willing to accept that he/she
- •might be treated with placebo during the treatment period.
- •3. Subject is able to apply/remove the trial patches correctly and consistently.
- •4. Subject is male or female, and is =18 and =75 years of age.
- •5. Subject meets the diagnosis of idiopathic RLS based on the 4 cardinal clinical
- •features according to the IRLSSG:
- •a. An urge to move legs, usually accompanied or caused by uncomfortable and
- •unpleasant sensations in the legs (The urge to move can be present without
- •uncomfortable sensations. Arms or other body parts can also be affected.).
- •b. The urge to move or unpleasant sensations begin or worsen during periods
- •of rest or inactivity such as lying or sitting.
- •c. The urge to move or unpleasant sensations are partially or totally relieved by
- •movement, such as walking or stretching, at least as long as the activity
- •d. The urge to move or unpleasant sensations are worse in the evening or night
- •than during the day or only occur in the evening or night (When symptoms
- •are very severe, the worsening at night may not be noticeable but must have
- •been previously present.).
- •6. Subject has had an initial response to previous dopaminergic treatment for RLS or
- •has had no previous dopaminergic treatment (ie, de novo).
- •7. The subject’s body mass index is =18kg/m2 and =35kg/m2.
- •8. At Baseline (Visit 2), subject has a score of =15 on the IRLS (indicating moderate
- •to severe RLS).
- •9. At Baseline (Visit 2), subject scores =4 points on the CGI Item 1 assessment
- •(indicating at least moderately ill).
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Subject has secondary RLS (eg, due to renal insufficiency [uremia], iron
- •anemia, or rheumatoid arthritis).
- •2. Subject has secondary RLS associated with previous or concomitant therapy with
- •dopamine D2 receptor antagonists, butyrophenones, metoclopramide, atypical
- •antipsychotics (eg, olanzapine), tri- and tetra-cyclic antidepressants, mianserine,
- •lithium, or due to withdrawal from drugs such as anticonvulsants,
- •benzodiazepines, barbiturates, and other hypnotics.
- •3. Subject has a current history of sleep disturbances like sleep apnea syndrome,
- •narcolepsy, sleep attacks/sudden onset of sleep, or myoclonus epilepsy either
- •observed during polysomnography or evidenced by subject history.
- •4. Subject has additional clinically relevant concomitant diseases such as
- •polyneuropathy, akathisia, claudication, varicosis, muscle fasciculation, painful
- •legs and moving toes, or radiculopathy.
- •5. Subject has other central nervous system diseases such as Parkinson’s disease,
- •dementia, progressive supranuclear paresis, multisystem atrophy, Huntington’s
- •Chorea, amyotrophic lateral sclerosis, or Alzheimer’s disease.
- •6. Subject has a prior history of psychotic episodes.
- •7. Subject has a history of chronic alcohol or drug abuse within the last 12 months.
- •8. Subject has any medical or psychiatric condition, which in the opinion of the
- •investigator, can jeopardize or would compromise the subject’s ability to
- •participate in this trial.
- •9. Subject has clinically relevant cardiac dysfunction and/or arrhythmias (eg,
- •suspected conduction system dysregulations, second or third degree AV block,
- •complete left or right bundle branch block, sick-sinus-syndrome, New York Heart
- •Association Class III or IV congestive heart failure, or has had a myocardial
- •infarction within 12 months prior to Screening [Visit 1]).
- •10. Subject has clinically relevant venous or arterial peripheral vascular disease.
- •11. Subject has clinically relevant renal dysfunction (serum creatinine >2.0mg/dL)
- •12. Subject has clinically relevant hepatic dysfunction (total bilirubin >2.0mg/dL or
- •alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) greater
- •than 2 times the upper limit of the reference range).
- •13. Subject has a malignant neoplastic disease requiring therapy within 12 months
- •prior to Screening (Visit 1).
- •14. Subject is currently receiving treatment with any of the following drug classes:
- •neuroleptics, hypnotics, antidepressants, anxiolytic drugs, anticonvulsive
- •therapy, opioids, benzodiazepines, monoamine oxidase (MAO) inhibitors,
- •catechol-O-methyl-transferase (COMT) inhibitors, sedative antihistamines,
- •psychostimulates, or amphetamines. If subject has received such therapy, a
- •washout period of at least 7 days prior to Baseline (Visit 2) is required before
- •starting treatment in this trial.
研究者
相似试验
进行中（未招募）
不适用
A mulit-center, randomized, double-blind, placebo-controlled, four-arm parallel group trial to investigate the efficacy and safety of three different transdermal doses of rotigotine in subjects with idiopathic restless legs syndromeRestless Leg's SyndromeMedDRA version: 7.0Level: LLTClassification code 10058920EUCTR2005-000428-18-DESchwarz Biosciences GmbH450
进行中（未招募）
不适用
A mulit-center, randomized, double-blind, placebo-controlled, four-arm parallel group trial to investigate the efficacy and safety of three different transdermal doses of rotigotine in subjects with idiopathic restless legs syndromeRestless Leg's SyndromeMedDRA version: 7.0Level: LLTClassification code 10058920EUCTR2005-000428-18-ATSchwarz Biosciences GmbH450
进行中（未招募）
不适用
A sleep laboratory study to investigate the safety and efficacy of the rotigotine skin patch in subjects with Restless Legs Syndrome and End-Stage Renal Disease requiring hemodialysisRestless Legs Syndrome in patients with End Stage Renal Disease (ESRD)MedDRA version: 14.1Level: SOCClassification code 10029205Term: Nervous system disordersSystem Organ Class: 10029205 - Nervous system disordersEUCTR2011-003486-15-DECB BIOSCIENCES GmbH48
进行中（未招募）
不适用
Study designed to demonstrate the efficacy and safety of Certolizumab pegol in combination with Methotrexate in the treatment of subjects suffering from early, progressive active rheumatoid arthritis.Early active rheumatoid arthritisMedDRA version: 17.1Level: LLTClassification code 10003268Term: Arthritis rheumatoidSystem Organ Class: 100000004859EUCTR2011-001729-25-DECB Pharma SA800
进行中（未招募）
不适用
Effect of vildagliptin on left ventricular function in patients with type 2 diabetes and congestive heart failureType 2 Diabetes. Heart failure (NYHA class I-III).MedDRA version: 13.1Level: PTClassification code 10067585Term: Type 2 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersMedDRA version: 13.1Level: LLTClassification code 10064081Term: Heart failure NYHA class IIISystem Organ Class: 10007541 - Cardiac disordersMedDRA version: 13.1Level: LLTClassification code 10064079Term: Heart failure NYHA class ISystem Organ Class: 10007541 - Cardiac disordersMedDRA version: 13.1Level: LLTClassification code 10064080Term: Heart failure NYHA class IISystem Organ Class: 10007541 - Cardiac disordersEUCTR2008-005012-41-LVovartis Pharma Services AG490